Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib

Autor:	Veerendra Munugalavadla, Lin Gu, Andrew D. Zelenetz, Jennifer R. Brown, Susan O'Brien, Richard R. Furman, Tadeusz Robak, Peter Hillmen, Anthony R. Mato, Marco Montillo, Ronald L. Dubowy, Nicole Lamanna
Rok vydání:	2020
Předmět:	Cancer Research medicine.medical_specialty business.industry Chronic lymphocytic leukemia Antineoplastic Agents Hematology medicine.disease Gastroenterology Leukemia Lymphocytic Chronic B-Cell Article Transaminase Oncology Purines Risk Factors Internal medicine medicine Humans In patient Idelalisib business Transaminases Quinazolinones
Zdroj:	Leukemia
ISSN:	1476-5551
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c8ef9fefa5b8aa43cda22854244dfd9 https://pubmed.ncbi.nlm.nih.gov/32655145 Zobrazit plný text záznamu Full text from SpringerLink